R-ISS

ورودی‌های بالینی بیمار

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
r iss
—stage
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • R-ISS III≥ 3
  • R-ISS II≥ 2
  • R-ISS I≥ 1
Direct Clinical Answer

The R-ISS calculates staging malignant disease, estimating overall survival, and assessing chemotherapy tolerability. Key inputs include iss stage. Scores guide adjusting systemic antineoplastic regimens, planning supportive palliative measures, or targeted monitoring. This standardized assessment improves clinical decision safety and bedside patient management.

Clinical Guidelines & Evidence

Revised International Staging System for multiple myeloma.

Clinical Indication

The R-ISS is indicated for bedside clinical practice to support Revised International Staging System for multiple myeloma.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients with solid tumors or hematologic malignancies undergoing staging, systemic therapy tolerability assessment, or prognostic stratification. Clinical application is indicated across Medical oncology clinics, chemotherapy infusion suites, inpatient oncology services, and palliative care.

Limitations & Contraindications

Prognostic indices provide statistical cohort survival estimates and must not replace individualized patient goals of care.

Clinical Pearls & Action Plan

Standardized functional performance status (ECOG or Karnofsky) is an independent determinant of chemotherapy tolerance and survival.

Formula & Variables:

R-ISS I: ISS I + normal LDH + standard CA; R-ISS III: ISS III + (high LDH or high-risk CA); else R-ISS II.

Input Parameters

NameTypeRequiredDescription
iss_stageintYesISS I/II/III (albumin + beta-2 microglobulin)
ldhstringYesLDH: normal, high
cytogeneticsstringYesHigh-risk: del(17p), t(4;14), t(14;16)

Score Interpretation & Guidance

RangeStageDescription
≥ 3R-ISS III5-yr OS ~40%
≥ 2R-ISS II5-yr OS ~62%
≥ 1R-ISS I5-yr OS ~82%

Evidence-Based References (EBM)

  • Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised International Staging System for multiple myeloma. J Clin Oncol. 2015;33(26):2863-2869.

Related calculators